183 related articles for article (PubMed ID: 9822896)
1. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Takano M; Hasegawa R; Fukuda T; Yumoto R; Nagai J; Murakami T
Eur J Pharmacol; 1998 Oct; 358(3):289-94. PubMed ID: 9822896
[TBL] [Abstract][Full Text] [Related]
2. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.
Raeissi SD; Hidalgo IJ; Segura-Aguilar J; Artursson P
Pharm Res; 1999 May; 16(5):625-32. PubMed ID: 10350002
[TBL] [Abstract][Full Text] [Related]
3. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
6. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Kim RB; Wandel C; Leake B; Cvetkovic M; Fromm MF; Dempsey PJ; Roden MM; Belas F; Chaudhary AK; Roden DM; Wood AJ; Wilkinson GR
Pharm Res; 1999 Mar; 16(3):408-14. PubMed ID: 10213372
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.
McCrea J; Prueksaritanont T; Gertz BJ; Carides A; Gillen L; Antonello S; Brucker MJ; Miller-Stein C; Osborne B; Waldman S
J Clin Pharmacol; 1999 Dec; 39(12):1212-20. PubMed ID: 10586386
[TBL] [Abstract][Full Text] [Related]
8. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
10. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
11. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells.
Gibbs MA; Baillie MT; Shen DD; Kunze KL; Thummel KE
Pharm Res; 2000 Mar; 17(3):299-305. PubMed ID: 10801218
[TBL] [Abstract][Full Text] [Related]
12. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.
Johnson BM; Charman WN; Porter CJ
Drug Metab Dispos; 2003 Sep; 31(9):1151-60. PubMed ID: 12920171
[TBL] [Abstract][Full Text] [Related]
13. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):391-402. PubMed ID: 15370956
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber.
Lampen A; Christians U; Gonschior AK; Bader A; Hackbarth I; von Engelhardt W; Sewing KF
Br J Pharmacol; 1996 Apr; 117(8):1730-4. PubMed ID: 8732283
[TBL] [Abstract][Full Text] [Related]
15. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.
Kinirons MT; Krivoruk Y; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Feb; 47(2):223-5. PubMed ID: 10190659
[No Abstract] [Full Text] [Related]
16. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
17. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.
Sandström R; Knutson TW; Knutson L; Jansson B; Lennernäs H
Br J Clin Pharmacol; 1999 Aug; 48(2):180-9. PubMed ID: 10417494
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4.
Achira M; Suzuki H; Ito K; Sugiyama Y
AAPS PharmSci; 1999; 1(4):E18. PubMed ID: 11741214
[TBL] [Abstract][Full Text] [Related]
19. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis.
Ragueneau-Majlessi I; Boulenc X; Rauch C; Hachad H; Levy RH
Curr Drug Metab; 2007 Dec; 8(8):810-4. PubMed ID: 18220561
[TBL] [Abstract][Full Text] [Related]
20. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Jamis-Dow CA; Pearl ML; Watkins PB; Blake DS; Klecker RW; Collins JM
Am J Clin Oncol; 1997 Dec; 20(6):592-9. PubMed ID: 9391548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
